Mikiko Nakamura1, Chao Xu2, Cheikh Diack3, Norihisa Ohishi1, Ruey-Min Lee2, Satofumi Iida1, Takehiko Kawanishi1, Toshihiko Ohtomo4, Ghassan K Abou-Alfa5, Ya-Chi Chen2. 1. Translational Clinical Research Science & Strategy Dept., Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. 2. Translational and Clinical Research Center, Hoffmann-La Roche Inc., New York City, USA. 3. Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland. 4. Project Planning & Coordination Dept., Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. 5. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
AIMS: Codrituzumab (GC33) is a recombinant, humanized mAb that binds to glypican-3 (GPC3), an oncofetal protein highly expressed in hepatocellular carcinoma (HCC). This investigation aimed to identify clinically relevant factors that may affect the overall survival (OS) in HCC patients treated withcodrituzumab and to quantitatively annotate their effects. METHODS:Codrituzumab exposure was estimated by a population pharmacokinetics model with a nonlinear elimination pathway. Analysis of OS was performed using a time-to-event model in 181 patients with advanced HCC. The model was tested with the addition of various covariates, including levels of immune biomarkers, such as CD16 (measured in terms of molecules of equivalent soluble fluorophore; CD16MESF ) and CD4, codrituzumab exposure and potential prognostic biomarkers of HCC such as baseline tumour size and soluble GPC3. RESULTS: The time-to-event model estimated a prolonged OS (>3 months) in patients with codrituzumab exposure of ≥230 μg ml-1 and high CD16MESF level (>5.26 × 105 MESF at least). The Weibull model was selected as the base hazard model. The baseline tumour size was included in the hazard model as a parameter independent of the drug effect. A logistic model was applied to explain the effects of drug exposure and CD16MESF level. CONCLUSIONS: The final model indicates that adequate drug exposure plus a favourable immune environment are associated with prolonged OS. This quantitative model should be further validated with emerging data so as to guide study design in future clinical trials.
RCT Entities:
AIMS: Codrituzumab (GC33) is a recombinant, humanized mAb that binds to glypican-3 (GPC3), an oncofetal protein highly expressed in hepatocellular carcinoma (HCC). This investigation aimed to identify clinically relevant factors that may affect the overall survival (OS) in HCC patients treated with codrituzumab and to quantitatively annotate their effects. METHODS:Codrituzumab exposure was estimated by a population pharmacokinetics model with a nonlinear elimination pathway. Analysis of OS was performed using a time-to-event model in 181 patients with advanced HCC. The model was tested with the addition of various covariates, including levels of immune biomarkers, such as CD16 (measured in terms of molecules of equivalent soluble fluorophore; CD16MESF ) and CD4, codrituzumab exposure and potential prognostic biomarkers of HCC such as baseline tumour size and soluble GPC3. RESULTS: The time-to-event model estimated a prolonged OS (>3 months) in patients with codrituzumab exposure of ≥230 μg ml-1 and high CD16MESF level (>5.26 × 105 MESF at least). The Weibull model was selected as the base hazard model. The baseline tumour size was included in the hazard model as a parameter independent of the drug effect. A logistic model was applied to explain the effects of drug exposure and CD16MESF level. CONCLUSIONS: The final model indicates that adequate drug exposure plus a favourable immune environment are associated with prolonged OS. This quantitative model should be further validated with emerging data so as to guide study design in future clinical trials.
Authors: Ghassan K Abou-Alfa; Oscar Puig; Bruno Daniele; Masatoshi Kudo; Philippe Merle; Joong-Won Park; Paul Ross; Jean-Marie Peron; Oliver Ebert; Stephen Chan; Tung Ping Poon; Massimo Colombo; Takuji Okusaka; Baek-Yeol Ryoo; Beatriz Minguez; Takayoshi Tanaka; Toshihiko Ohtomo; Stacey Ukrainskyj; Frederic Boisserie; Olga Rutman; Ya-Chi Chen; Chao Xu; Eliezer Shochat; Lori Jukofsky; Bernhard Reis; Gong Chen; Laura Di Laurenzio; Ray Lee; Chia-Jui Yen Journal: J Hepatol Date: 2016-04-13 Impact factor: 25.083
Authors: Andrew X Zhu; Philip J Gold; Anthony B El-Khoueiry; Thomas A Abrams; Hideo Morikawa; Norihisa Ohishi; Toshihiko Ohtomo; Philip A Philip Journal: Clin Cancer Res Date: 2013-01-29 Impact factor: 12.531
Authors: Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971
Authors: Stephen Ph Alexander; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; O Peter Buneman; John A Cidlowski; Arthur Christopoulos; Anthony P Davenport; Doriano Fabbro; Michael Spedding; Jörg Striessnig; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: Michael V Ortiz; Stephen S Roberts; Julia Glade Bender; Neerav Shukla; Leonard H Wexler Journal: Front Oncol Date: 2019-02-26 Impact factor: 6.244